Respiratory Medicine Research Institute of Michigan, PLC | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Recruiting	Phase 3	2026-10-06		NCT07783425
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, immune system disorder, nasal disorder, otorhinolaryngologic disease, perennial allergic rhinitis, respiratory system disorder, rhinitis	Active, not recruiting	Phase 3	2026-09-24		NCT06339008
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Enrolling by invitation	Phase 3	2026-07-30		NCT05735483
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Active, not recruiting	Phase 3	2026-07-30		NCT05559359